Should aspirin be used for the primary prevention of cardiovascular disease in the general population?
Department of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, PR China.
Qing-Yu
QY
Huang
Ren-Qiang
RQ
Yang
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods; D014481:United States; D014486:United States Food and Drug Administration
D010975:Platelet Aggregation Inhibitors; D001241:Aspirin